KLRB1 is a novel prognostic biomarker in endometrial cancer and is associated with immune infiltration
Abstract Background: Endometrial cancer (EC) has the characteristics of high mortality and poor prognosis in the advanced stage, which seriously threatens women’s health. Killer cell lectin-like receptor B1 (KLRB1) is a promising immune checkpoint of which the expression level can regulate the killing effect on tumor cells of the immune system, thereby affecting the survival and prognosis of tumor patients. However, it is still unclear whether KLRB1 is associated with survival and prognosis in patients with EC. Therefore, our study
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in
